User login

Froman: Biologics Is The Major Outstanding TPP Issue For Congress

June 16, 2016 at 8:40 PM
The length of data protection provided to biologic drugs under the Trans-Pacific Partnership is the "main outstanding issue" that Congress has with the trade agreement, U.S. Trade Representative Michael Froman said on June 14. Members are seeking assurances that biologics will be provided eight years of market exclusivity in TPP and that the deal will not subvert the 12 years of protection for biologics provided by U.S. law, he said. "We ended up at eight years," Froman said at the...

Not a subscriber? You can request 30 days free access to exclusive, behind-the-scenes reporting on trade policy in the Biden era.